This study is a multicenter, open-label, non-randomized study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with Non-Segmental Vitiligo
The subject fully understands this study and is able to comply with the relevant trial procedures. The subject and their legal guardian voluntarily sign the informed consent form (ICF).
Age 12 to 18 years inclusive (including 12 years old, excluding 18 years old) at the time of signing the ICF, both genders, with body weight ≥ 30 kg.
Subjects with a clinical diagnosis of non-segmental vitiligo
Pregnant or breastfeeding women, or subjects planning to become pregnant or breastfeed during the study period.
Trial participants with complete depigmentation of hair within the vitiligo area.
Trial participants clinically diagnosed with segmental vitiligo, mucosal non-segmental vitiligo, or other cutaneous depigmentation disorders.
Single group
VC005 tablets
DrugVC005 repeat administration for up to 24 weeks
Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUC）
Peak Plasma Concentration (Cmax）
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
